 |
|
|
| |
Integrated Safety Analysis of Sofosbuvir-Based HCV Treatment Regimens From Phase 3 Studies
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Stuart C. Gordon,1 William J. Towner,2 Avanish M. Aggarwal,3 Julie Ma,4 John McNally,4 Luisa M. Stamm,4 Diana M. Brainard,4 William T. Symonds,4 John G. McHutchison,4 Nicholas Bellos,5 Karen T. Tashima,6 Nezam H. Afdhal7
1Henry Ford Health System, Detroit, Michigan, USA; 2Kaiser Permanente, Los Angeles, California, USA; 3Central Florida Gastroenterology, Orlando, Florida, USA; 4Gilead Sciences, Inc., Foster City, California, USA; 5Southwest Infectious Disease, PA, Dallas, Texas, USA; 6The Miriam Hospital, Providence, Rhode Island, USA; 7Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
|
| |
|
|
|
|
|
